US cost-effectiveness of polatuzumab vedotin, bendamustine and rituximab in diffuse large B-cell lymphoma

被引：7
|
作者：
Betts, Keith A. [1 ]
Thuresson, Per-Olof [2 ]
Felizzi, Federico [2 ]
Du, Ella X. [1 ]
Dieye, Ibou [3 ]
Li, Jia [4 ]
Schulz, Mathias [4 ]
Masaquel, Anthony S. [4 ]
机构：
[1] Anal Grp Inc, Los Angeles, CA 90071 USA
[2] F Hoffmann La Roche Ltd, Basel, Switzerland
[3] Anal Grp Inc, Boston, MA 02199 USA
[4] Genentech Inc, San Francisco, CA 94080 USA
来源：
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH | 2020年 / 9卷 / 14期
关键词：
bendamustine; cost-effectiveness; DLBCL; polatuzumab vedotin; relapsed; refractory; rituximab; SALVAGE REGIMENS; TRANSPLANTATION;
D O I：
10.2217/cer-2020-0057
中图分类号：
R19 [保健组织与事业（卫生事业管理）];
学科分类号：
摘要：
Aim: To evaluate the cost-effectiveness of polatuzumab vedotin (pola) + bendamustine + rituximab (BR) in relapsed/refractory diffuse large B-cell lymphoma based on the GO29365 trial from a US payer's perspective.Materials & methods: A partitioned survival model used progression-free survival and overall survival data from the GO29365 trial. The base case analysis assumed overall survival was informed by progression-free survival; a mixture cure model estimated proportion of long-term survivors.Results:In the base case, pola + BR was cost-effective versus BR at US$35,864 per quality-adjusted life year gained. Probabilistic and one-way sensitivity analyses showed that the findings were robust.Conclusion:Pola + BR is cost-effective versus BR for the treatment of transplant-ineligible relapsed/refractory diffuse large B-cell lymphoma in the US.
引用
收藏
页码：1003 / 1015
页数：13
相关论文
共 50 条
  • [11] Polatuzumab vedotin combined with bendamustine and rituximab for relapsed/refractory diffuse large B-cell lymphoma: A systematic review protocol
    Eslami, Mohammadreza
    Mehrabi, Mahdi
    Payandeh, Mehrdad
    Saba, Fakhredin
    [J]. PLOS ONE, 2024, 19 (08):
  • [12] Polatuzumab vedotin plus bendamustine and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma in the real world
    Vodicka, Prokop
    Benesova, Katerina
    Janikova, Andrea
    Prochazka, Vit
    Belada, David
    Mocikova, Heidi
    Steinerova, Katerina
    Duras, Juraj
    Karban, Josef
    Hanackova, Veronika
    Sykorova, Alice
    Obr, Ales
    Trneny, Marek
    [J]. EUROPEAN JOURNAL OF HAEMATOLOGY, 2022, 109 (02) : 162 - 165
  • [13] COST-EFFECTIVENESS AND COST-UTILITY ANALYSES OF POLATUZUMAB VEDOTIN WITH RITUXIMAB AND CHEMOTHERAPY VS RITUXIMAB AND CHEMOTHERAPY IN TREATING NAIVE DIFFUSE LARGE B-CELL LYMPHOMA IN ITALY
    Bellone, M.
    Pradelli, L.
    Ghislieri, D.
    [J]. VALUE IN HEALTH, 2022, 25 (12) : S75 - S76
  • [14] Acute Pancreatitis Induced by Polatuzumab-Vedotin-Piiq in Combination With Bendamustine and Rituximab for Diffuse Large B-Cell Lymphoma
    Anderson, Kara
    Shehata, Mena
    Singh, Davinder
    Al-Ourani, Mohammed
    [J]. CUREUS JOURNAL OF MEDICAL SCIENCE, 2020, 12 (09)
  • [15] POLATUZUMAB VEDOTIN-RITUXIMAB-BENDAMUSTINE IN DIFFUSE LARGE CELL B LYMPHOMA: EXPERIENCE IN OUR CENTER
    Amarilla, Lanzas Irene Florencia
    Pimentel, Feliciano Ana Isabel
    Gracia, Piquer Raquel
    Rivas, Estaben Irene
    Ortiz, Lopez Alicia
    Gemperle, Ortiz Natalia
    Angos, Vazquez Sonia
    Dourdil, Sahun Maria Victoria
    Bonafonte, Arruga Maria Elena
    Martinez, Lazaro Beatriz
    Palomera, Bernal Luis Ramon
    [J]. HAEMATOLOGICA, 2020, 105 : 295 - 295
  • [16] COST-EFFECTIVENESS ANALYSIS OF POLATUZUMAB VEDOTIN COMBINED WITH CHEMOIMMUNOTHERAPY IN UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) IN CHINA
    Bai, X.
    Shao, R.
    Zhen, B.
    Xia, Y.
    He, X.
    [J]. VALUE IN HEALTH, 2023, 26 (12) : S189 - S189
  • [17] Polatuzumab Vedotin in Combination with Bendamustine Plus Rituximab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Our Experience
    Darcin, Tahir
    Yigenoglu, Tugce Nur
    Sahin, Derya
    Bakirtas, Mehmet
    Basci, Semih
    Merdin, Alparslan
    Yildiz, Jale
    Ulu, Bahar Uncu
    Tetik, Aysegul
    Iskender, Dicle
    Cakar, Merih Kizil
    Dal, Mehmet Sinan
    Altuntas, Fevzi
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S249 - S250
  • [18] Cost-effectiveness of combination therapy of polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisolone for previously untreated diffuse large B-cell lymphoma in Japan
    Mizuoka, Takashi
    Sakamaki, Hiroyuki
    Fuji, Shigeo
    Saito, Shota
    Murata, Tatsunori
    Ohno, Shinya
    Inubashiri, Naoki
    Oshima, Tomoha
    Yamamoto, Kazuhito
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2023, 26 (01) : 1122 - 1133
  • [19] Polatuzumab vedotin in combination with rituximab and bendamustine (Pola-RB) for relapsed primary cutaneous diffuse large B-cell lymphoma
    Wilms, L.
    Oymanns, M.
    Huenerlituerkoglu, A.
    Dippel, E.
    Assaf, C.
    [J]. EUROPEAN JOURNAL OF CANCER, 2022, 173 : S25 - S25
  • [20] A phase 2 study of polatuzumab vedotin plus bendamustine plus rituximab in relapsed/refractory diffuse large B-cell lymphoma
    Terui, Yasuhito
    Rai, Shinya
    Izutsu, Koji
    Yamaguchi, Motoko
    Takizawa, Jun
    Kuroda, Junya
    Ishikawa, Takayuki
    Kato, Koji
    Suehiro, Youko
    Fukuhara, Noriko
    Ohmine, Ken
    Goto, Hideki
    Yamamoto, Kazuhito
    Kanemura, Nobuhiro
    Ueda, Yasunori
    Ishizawa, Kenichi
    Kumagai, Kyoya
    Kawasaki, Atsuko
    Saito, Tomohisa
    Hashizume, Misato
    Shibayama, Hirohiko
    [J]. CANCER SCIENCE, 2021, 112 (07) : 2845 - 2854
12345